{"id":1464,"date":"2022-11-14T10:30:24","date_gmt":"2022-11-14T09:30:24","guid":{"rendered":"https:\/\/napotherapeutics.com\/2022\/11\/14\/press-ema-crofelemer-ottiene-unulteriore-designazione-di-farmaco-orfano-anche-per-la-malattia-da-inclusioni-microvillari\/"},"modified":"2022-11-14T10:52:21","modified_gmt":"2022-11-14T09:52:21","slug":"news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease","status":"publish","type":"post","link":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/","title":{"rendered":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)"},"content":{"rendered":"[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” disable_element=”yes” advanced_gradient_angle=”0″ overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none” gradient_type=”default” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_spacing=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” el_class=”news-header-image-column” advanced_gradient_angle=”0″ gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid” gradient_type=”default”][image_with_animation image_url=”1468″ image_size=”full” animation_type=”entrance” animation=”None” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][\/vc_column][\/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” top_margin=”20px” column_element_spacing=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” advanced_gradient_angle=”0″ gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid” gradient_type=”default”][vc_column_text]\n

After Short Bowel syndrome (SBS) designation, Napo Therapeutics gains another major Crofelemer’s orphan drug status approval for treatment of the very rare microvillary inclusion disease (MVID). The condition, characterized by untreatable neonatal secretory diarrhea, affects children from birth, condemning them to the risk of serious complications and to feed for life through parenteral therapy. <\/i> Today, in the European Union 0.1 people out of 10,000 suffer from it.<\/p>\n

In 2021 Napo Therapeutics, a European start-up based in Milan, was born in order to allow patients fighting against rare diseases to access therapies that finally make a difference in the quality of life. led by a team of professionals with long experience in the world of BiG Pharma who have chosen to dedicate themselves to the treatment of rare diseases and pathologies with a strong unmet medical needs. The EMA’s decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.<\/p>\n[\/vc_column_text][vc_column_text]Read the press release<\/a>[\/vc_column_text][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"

Napo Therapeutics gains another major Crofelemer’s orphan drug status approval for treatment of the very rare microvillary inclusion disease (MVID)<\/p>\n","protected":false},"author":1,"featured_media":1468,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":{"0":"post-1464","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news-en"},"yoast_head":"\nEma, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics<\/title>\n<meta name=\"description\" content=\"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Napo Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T09:30:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-14T09:52:21+00:00\" \/>\n<meta name=\"author\" content=\"jamarea\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/11\/news-pattern-3.svg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"jamarea\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\"},\"author\":{\"name\":\"jamarea\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/3c9a97cbef41bf691202f7da36742c11\"},\"headline\":\"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)\",\"datePublished\":\"2022-11-14T09:30:24+00:00\",\"dateModified\":\"2022-11-14T09:52:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\"},\"wordCount\":542,\"publisher\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\",\"url\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\",\"name\":\"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/#website\"},\"datePublished\":\"2022-11-14T09:30:24+00:00\",\"dateModified\":\"2022-11-14T09:52:21+00:00\",\"description\":\"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.\",\"breadcrumb\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/napotherapeutics.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#website\",\"url\":\"https:\/\/napotherapeutics.com\/en\/\",\"name\":\"Napo Therapeutics\",\"description\":\"Societ\u00e0 farmaceutica europea indipendente per la cura di malattie rare\",\"publisher\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/napotherapeutics.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#organization\",\"name\":\"Napo Therapeutics\",\"url\":\"https:\/\/napotherapeutics.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/07\/logo-napo.svg\",\"contentUrl\":\"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/07\/logo-napo.svg\",\"width\":150,\"height\":62,\"caption\":\"Napo Therapeutics\"},\"image\":{\"@id\":\"https:\/\/napotherapeutics.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/3c9a97cbef41bf691202f7da36742c11\",\"name\":\"jamarea\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/dd58508381bd0c1540d4ce9b062e0103ab55b702455811132db2d6b72ab64e75?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/dd58508381bd0c1540d4ce9b062e0103ab55b702455811132db2d6b72ab64e75?s=96&d=blank&r=g\",\"caption\":\"jamarea\"},\"sameAs\":[\"https:\/\/napotherapeutics.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics","description":"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/","og_locale":"en_US","og_type":"article","og_title":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics","og_description":"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.","og_url":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/","og_site_name":"Napo Therapeutics","article_published_time":"2022-11-14T09:30:24+00:00","article_modified_time":"2022-11-14T09:52:21+00:00","author":"jamarea","twitter_card":"summary_large_image","twitter_image":"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/11\/news-pattern-3.svg","twitter_misc":{"Written by":"jamarea","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#article","isPartOf":{"@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/"},"author":{"name":"jamarea","@id":"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/3c9a97cbef41bf691202f7da36742c11"},"headline":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)","datePublished":"2022-11-14T09:30:24+00:00","dateModified":"2022-11-14T09:52:21+00:00","mainEntityOfPage":{"@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/"},"wordCount":542,"publisher":{"@id":"https:\/\/napotherapeutics.com\/en\/#organization"},"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/","url":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/","name":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID) - Napo Therapeutics","isPartOf":{"@id":"https:\/\/napotherapeutics.com\/en\/#website"},"datePublished":"2022-11-14T09:30:24+00:00","dateModified":"2022-11-14T09:52:21+00:00","description":"Today, in the European Union 0.1 people out of 10,000 suffer from it. The EMA's decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.","breadcrumb":{"@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/napotherapeutics.com\/en\/2022\/11\/14\/news_ema-crofelemer-obtains-an-additional-orphan-drug-designation-also-for-microvillary-inclusion-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/napotherapeutics.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)"}]},{"@type":"WebSite","@id":"https:\/\/napotherapeutics.com\/en\/#website","url":"https:\/\/napotherapeutics.com\/en\/","name":"Napo Therapeutics","description":"Societ\u00e0 farmaceutica europea indipendente per la cura di malattie rare","publisher":{"@id":"https:\/\/napotherapeutics.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/napotherapeutics.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/napotherapeutics.com\/en\/#organization","name":"Napo Therapeutics","url":"https:\/\/napotherapeutics.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/napotherapeutics.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/07\/logo-napo.svg","contentUrl":"https:\/\/napotherapeutics.com\/wp-content\/uploads\/2022\/07\/logo-napo.svg","width":150,"height":62,"caption":"Napo Therapeutics"},"image":{"@id":"https:\/\/napotherapeutics.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/3c9a97cbef41bf691202f7da36742c11","name":"jamarea","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/napotherapeutics.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/dd58508381bd0c1540d4ce9b062e0103ab55b702455811132db2d6b72ab64e75?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dd58508381bd0c1540d4ce9b062e0103ab55b702455811132db2d6b72ab64e75?s=96&d=blank&r=g","caption":"jamarea"},"sameAs":["https:\/\/napotherapeutics.com"]}]}},"_links":{"self":[{"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1464"}],"version-history":[{"count":0,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1464\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/media\/1468"}],"wp:attachment":[{"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/napotherapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}